Piper Sandler initiated coverage on Waters with a new price target
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
Piper Sandler initiated coverage of Waters with a rating of Neutral and set a new price target of $400.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2026 | $400.00 | Neutral | Piper Sandler |
| 6/2/2026 | $425.00 | Outperform | Wolfe Research |
| 4/6/2026 | $350.00 | In-line → Outperform | Evercore ISI |
| 2/10/2026 | $360.00 | In-line | Evercore ISI |
| 2/10/2026 | $425.00 | Buy | Citigroup |
| 2/10/2026 | $400.00 | Overweight | Barclays |
| 1/6/2026 | $440.00 | Buy | Guggenheim |
| 1/5/2026 | Outperform | William Blair |
IMU’s AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.Waters Biosciences’ technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU’s AI analytics in research to deliver deeper, population-level disease insights.Partnership supports IMU’s expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE:WAT) today anno
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway.Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.Industry-leading Coin Cell DSC temperature range from –80 °C to 600 °C, aiding battery development and QA/QC.MILFORD, Mass., June 9, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced the launch of the Waters TA Instruments™ Coin Cell Differential Scanning Calorimeter (DSC), designed to transform battery safety testing. Purpose-built for battery scientists, the Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-intensive prepa
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics.MILFORD, Mass., June 8, 2026 /CNW/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-o
SD - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
Piper Sandler initiated coverage of Waters with a rating of Neutral and set a new price target of $400.00
Wolfe Research resumed coverage of Waters with a rating of Outperform and set a new price target of $425.00
Evercore ISI upgraded Waters from In-line to Outperform and set a new price target of $350.00
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies
MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
First Quarter 2026 HighlightsTotal reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses.Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.The Biosciences and Diagnostic Solutions businesses generated $520 million of reported revenue since the closing of the acquisition – $40 million above guidance – driven by traction from commercial execution and o
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time. About Waters CorporationWaters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innova
Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in